Lancet
-
Randomized Controlled Trial Multicenter Study Comparative Study
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Dalcetrapib modulates cholesteryl ester transfer protein (CETP) activity to raise high-density lipoprotein cholesterol (HDL-C). After the failure of torcetrapib it was unknown if HDL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties. dal-PLAQUE is the first multicentre study using novel non-invasive multimodality imaging to assess structural and inflammatory indices of atherosclerosis as primary endpoints. ⋯ F Hoffmann-La Roche Ltd.
-
Randomized Controlled Trial Multicenter Study
Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial.
The increasing prevalence of overweight and obesity needs effective approaches for weight loss in primary care and community settings. We compared weight loss with standard treatment in primary care with that achieved after referral by the primary care team to a commercial provider in the community. ⋯ Weight Watchers International, through a grant to the UK Medical Research Council.